Global Genomics Group (G3) and GNS Healthcare Report Preliminary Results of Largest-Ever …

ATLANTA & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Global Genomics Group (G3), a life sciences company that leverages large-scale genomic and molecular disease profiles to develop life-changing diagnostics and therapeutics, and GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to match health interventions to individual patients and discover new target intervention pathways, today announced preliminary results of the GLOBAL Clinical Study designed to identify biomarkers associated with coronary artery disease (CAD). The study provided proof of concept of the approach by prospectively identifying a biochemical pathway known to be associated with CAD. The GLOBAL Clinical Study is the first large-scale study that leverages pan-omic measurements, including whole genome sequencing, whole genome methylation, whole transcriptome sequencing, unbiased proteomics, metabolomics, lipidomics, and lipoprotein proteomics, in a specific clinically-relevant patient population –…


Link to Full Article: Global Genomics Group (G3) and GNS Healthcare Report Preliminary Results of Largest-Ever …